A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

• * Relapsed or refractory multiple myeloma (MM) and must:
• 1. have documented disease progression during or after their last myeloma therapy
• 2. be refractory to, intolerant to, or not a candidate for available, established therapies known to provide clinical benefit in MM
• * Must have measurable disease
• * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
• * Agree to follow the CC-92480 Pregnancy Prevention Plan (PPP)
• * Known active or history of central nervous system (CNS) involvement of MM
• * Plasma cell leukemia; Waldenstrom's macroglobulinemia; polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome; or clinically significant light-chain amyloidosis.
• * Impaired cardiac function or clinically significant cardiac disease
• * Previous SARS-CoV-2 infection within 14 days for asymptomatic or mild symptomatic infections or 28 days for severe/critical illness prior to Cycle 1 Day 1 (C1D1)
• * For Part 1: received prior therapy with CC-92480
• * For Part 2: received prior therapy with CC-92480, tazemetostat, BMS-986158, or trametinib
• * Previously received allogeneic stem-cell transplant at any time or received autologous stem-cell transplant within 12 weeks of initiating study treatment
• * Received any of the following within 14 days prior to initiating study treatment:
• 1. Plasmapheresis
• 2. Major surgery
• 3. Radiation therapy other than local therapy for myeloma associated bone lesions
• 4. Use of any systemic anti-myeloma drug therapy
• * Used any investigational agents within 28 days or 5 half-lives (whichever is shorter) prior to initiating study treatment
• * COVID-19 vaccine within 14 days prior to C1D1